Restoration of t cell substes of patients with type 1 diabetes mellitus by microencapsulated human umbilical cord Wharton jelly-derived mesenchymal stem cells An in vitro study

Restoration of t cell substes of patients with type 1 diabetes mellitus by microencapsulated human umbilical cord Wharton jelly-derived mesenchymal stem cells : An in vitro study

Copyright © 2015. Published by Elsevier Inc.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 163(2016) vom: 15. Feb., Seite 34-41
1. Verfasser: Montanucci, Pia (VerfasserIn)
Weitere Verfasser: Alunno, Alessia, Basta, Giuseppe, Bistoni, Onelia, Pescara, Teresa, Caterbi, Sara, Pennoni, Ilaria, Bini, Vittorio, Gerli, Roberto, Calafiore, Riccardo
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2016
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, Non-U.S. Gov't Adult mesenchymal stem cell HLAG-5 Immunomodulation Microencapsulation Proliferation inhibition Type 1 diabetes mellitus Antiviral Agents Capsules mehr... FOXP3 protein, human Forkhead Transcription Factors HLA-G Antigens IDO1 protein, human IL10 protein, human IL17A protein, human IL2 protein, human IL6 protein, human Indoleamine-Pyrrole 2,3,-Dioxygenase Interleukin-17 Interleukin-2 Interleukin-6 Interleukins TNF protein, human Transforming Growth Factor beta Tumor Necrosis Factor-alpha Interleukin-10 130068-27-8 Interferon-gamma 82115-62-6 NOS2 protein, human EC 1.14.13.39 Nitric Oxide Synthase Type II Hypoxanthine Phosphoribosyltransferase EC 2.4.2.8 Interleukin-21 MKM3CA6LT1
Beschreibung
Zusammenfassung:Copyright © 2015. Published by Elsevier Inc.
Human umbilical cord Wharton jelly-derived mesenchymal stem cells (hUCMS) might apply to treating chronic autoimmune disorders, as already shown for Sjögren's syndrome, including type 1 diabetes mellitus (T1D). Since naked hUCMS grafts encountered restraints, we enveloped hUCMS, within immunoisolatory microcapsules (CpS-hUCMS), made of our endotoxin-free, clinical grade alginate. We then examined the vitro effects of interferon (IFN)-γ-pretreated CpS-hUCMS on Th17 and Treg of T1D patients (n=15) and healthy controls (n=10). Peripheral blood mononuclear cells (PBMCs) were co-cultured with PBMC/CpS-hUCMS: lymphocyte proliferation was assessed by carboxyfluorescein succinimidyl esther (CFSE) dilution assay, and phenotypic analysis of regulatory and effector Tc was also performed. Cytokine expression was performed by bead array and qPCR on IFN-γ-pretreated hUCMS before PBMCs co-culture. CpS-hUCMS restored a correct Treg/Th17 ratio, relevant to the T1D disease process. In summary, we have preliminarily developed a new biohybrid system, associated with immunoregulatory properties, that is ready for in vivo application
Beschreibung:Date Completed 28.06.2016
Date Revised 03.01.2025
published: Print-Electronic
Citation Status MEDLINE
ISSN:1521-7035
DOI:10.1016/j.clim.2015.12.002